Antianemic Treatment of Cancer Patients in German Routine Practice: Data from a Prospective Cohort Study - The Tumor Anemia Registry

Anemia

Volumn 2016, Issue , 2016, Pages

  Steinmetz, Tilman ^a   Schröder, Jan ^b   Plath, Margarete ^c   Link, Hartmut ^d   Vogt, Michèle ^e   Frank, Melanie ^e   Marschner, Norbert ^f  

^a Outpatient Clinic for Oncology and Haematology   (Germany)

^b Outpatient Clinic for Oncology   (Germany)

^c Outpatient Clinic for Oncology   (Germany)

^d Westpfalz Klinikum GmbH   (Germany)

^e iOMEDICO   (Germany)

^f Outpatient Clinic for Interdisciplinary Oncology and Hematology   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84959422663     PISSN: 20901267     EISSN: 20901275     Source Type: Journal    
DOI: 10.1155/2016/8057650     Document Type: Article

References (26)

1. WHO, "Haemoglobin concentrations for the diagnosis of anaemia and assessment of severity," Vitamin and Mineral Nutrition Information System, Geneva, Switzerland, World Health Organization (WHO/NMH/NHD/MNM/11. 1), 2011, http://www. who. int/vmnis/indicators/haemoglobin. pdf.
2. H. Ludwig, S. Van Belle, P. Barrett-Lee et al., "The European Cancer Anaemia Survey (ECAS): A large, multinational, prospective survey defining the prevalence, incidence, and treatment of anaemia in cancer patients," European Journal of Cancer, vol. 40, no. 15, pp. 2293-2306, 2004.
3. T. Steinmetz, U. Totzke, M. Schweigert et al., "A prospective observational study of anaemia management in cancer patients-results from the German Cancer Anaemia Registry," European Journal of Cancer Care, vol. 20, no. 4, pp. 493-502, 2011.
4. G. Birgegard, P. Gascón, andH. Ludwig, "Evaluationof anaemia in patients with multiple myeloma and lymphoma: findings of the European CANCER ANAEMIA SURVEY," European Journal of Haematology, vol. 77, no. 5, pp. 378-386, 2006.
5. P. J. Barrett-Lee, H. Ludwig, G. Birgegard et al., "Independent risk factors for anemia in cancer patients receiving chemotherapy: results from the European Cancer Anaemia Survey," Oncology, vol. 70, no. 1, pp. 34-48, 2006.
6. J. Bohlius, T. Tonia, E. Nüesch et al., "Effects of erythropoiesisstimulating agents on fatigue-and anaemia-related symptoms in cancer patients: systematic review and meta-analyses of published and unpublished data," British Journal of Cancer, vol. 111, no. 1, pp. 33-45, 2014.
7. T. Steinmetz, M. Kindler, O. Lange, U. Vehling-Kaiser, A. Kuhn, and E. Hellebrand, "A prospective cohort study on the impact of darbepoetin alfa on quality of life in daily practice following anemia treatment guideline revisions," Current Medical Research and Opinion, vol. 30, no. 9, pp. 1813-1820, 2014.
8. J. L. Spivak, P. Gascón, and H. Ludwig, "Anemia management in oncology and hematology," Oncologist, vol. 14, supplement 1, pp. 43-56, 2009.
9. D. Cella, M. J. Zagari, C. Vandoros, D. D. Gagnon,H.-J. Hurtz, and J. W. R. Nortier, "Epoetin alfa treatment results in clinically significant improvements in quality of life in anemic cancer patients when referenced to the general population," Journal of Clinical Oncology, vol. 21, no. 2, pp. 366-373, 2003.
10. M. S. Aapro and H. Link, "September 2007 update on EORTC guidelines and anemia management with erythropoiesisstimulating agents," Oncologist, vol. 13, supplement 3, pp. 33-36, 2008.
11. J. D. Rizzo, M. Brouwers, P. Hurley et al., "American Society of Clinical Oncology/American Society of Hematology clinical practice guideline update on the use of epoetin and darbepoetin in adult patients with cancer," Journal of Clinical Oncology, vol. 28, no. 33, pp. 4996-5010, 2010.
12. NCCN, NCCN Clinical Practice Guidelines in Oncology: Cancerand Chemotherapy-Induced Anemia, Version 2. 2015, National Comprehensive Cancer Network, 2015, http://www. nccn. org/professionals/physician gls/pdf/anemia. pdf.
13. Bundesärztekammer BAK (German Medical Association), "Cross-sectional guidelines for therapy with blood components and plasma derivatives-4th revised edition," Transfusion Medicine and Hemotherapy, vol. 36, pp. 345-492, 2009.
14. K. Webster, D. Cella, and K. Yost, "The Functional Assessment of Chronic Illness Therapy (FACIT) measurement system: properties, applications, and interpretation," Health and Quality of Life Outcomes, vol. 1, article 79, 2003.
15. J. Ringash, B. O'Sullivan, A. Bezjak, and D. A. Redelmeier, "Interpreting clinically significant changes in patient-reported outcomes," Cancer, vol. 110, no. 1, pp. 196-202, 2007.
16. M. E. Charlson, P. Pompei, K. L. Ales, and C. R. MacKenzie, "A new method of classifying prognostic comorbidity in longitudinal studies: development and validation," Journal of Chronic Diseases, vol. 40, no. 5, pp. 373-383, 1987.
17. FACIT. org, "FACT-An Scoring Guidelines," Version 4, May 2003.
18. A. Calabrich and A. Katz, "Management of anemia in cancer patients," Future Oncology, vol. 7, no. 4, pp. 507-517, 2011.
19. M. L. Thomas, "Anemia and quality of life in cancer patients: impact of transfusion and erythropoietin," Medical Oncology, vol. 15, supplement 1, pp. S13-S18, 1998.
20. P. J. Barrett-Lee, N. P. Bailey, M. E. R. O'Brien, and E. Wager, "Large-scale UK audit of blood transfusion requirements and anaemia in patients receiving cytotoxic chemotherapy," British Journal of Cancer, vol. 82, no. 1, pp. 93-97, 2000.
21. C. Bokemeyer, M. S. Aapro, A. Courdi et al., "EORTCguidelines for the use of erythropoietic proteins in anaemic patients with cancer: 2006 update," European Journal of Cancer, vol. 43, no. 2, pp. 258-270, 2007.
22. T. Tonia and J. Bohlius, "Ten years ofmeta-analyses on erythropoiesis-stimulating agents in cancer patients," in Hematopoietic Growth Factors in Oncology, vol. 157 of Cancer Treatment and Research, pp. 217-238, Springer, Berlin, Germany, 2011.
23. T. Tonia, A. Mettler, N. Robert et al., "Erythropoietin or darbepoetin for patients with cancer," Cochrane Database of Systematic Reviews, vol. 12,Article IDCD003407, 2012.
24. H. T. Steinmetz, A. Tsamaloukas, S. Schmitz et al., "A new concept for the differential diagnosis and therapy of anaemia in cancer patients," Supportive Care in Cancer, vol. 19, no. 2, pp. 261-269, 2010.
25. C. Thomas and L. Thomas, "Biochemical markers and hematologic indices in the diagnosis of functional iron deficiency," Clinical Chemistry, vol. 48, no. 7, pp. 1066-1076, 2002.
26. S. B. Yellen, D. F. Cella, K. Webster, C. Blendowski, and E. Kaplan, "Measuring fatigue and other anemia-related symptoms with the Functional Assessment of Cancer Therapy (FACT) measurement system," Journal of Pain and Symptom Management, vol. 13, no. 2, pp. 63-74, 1997.